These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

747 related items for PubMed ID: 19053049

  • 1. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.
    Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA.
    Hepatology; 2009 Jan; 49(1):80-6. PubMed ID: 19053049
    [Abstract] [Full Text] [Related]

  • 2. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
    Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.
    Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
    [Abstract] [Full Text] [Related]

  • 3. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease.
    Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, Leshno M, Blendis L, Halpern Z, Oren R.
    Clin Gastroenterol Hepatol; 2006 May; 4(5):639-44. PubMed ID: 16630771
    [Abstract] [Full Text] [Related]

  • 4. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.
    Anderson JW, Schwartz SM, Hauptman J, Boldrin M, Rossi M, Bansal V, Hale CA.
    Ann Pharmacother; 2006 Oct; 40(10):1717-23. PubMed ID: 16940406
    [Abstract] [Full Text] [Related]

  • 5. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B, Tonstad S, Rössner S, Toubro S, Niskanen L, Madsbad S, Mustajoki P, Rissanen A.
    Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
    [Abstract] [Full Text] [Related]

  • 6. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients.
    Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P.
    Aliment Pharmacol Ther; 2004 Sep 15; 20(6):623-8. PubMed ID: 15352910
    [Abstract] [Full Text] [Related]

  • 7. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.
    Rowe R, Cowx M, Poole C, McEwan P, Morgan C, Walker M.
    Curr Med Res Opin; 2005 Nov 15; 21(11):1885-90. PubMed ID: 16307710
    [Abstract] [Full Text] [Related]

  • 8. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease.
    Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, David E, Rizzetto M, Marchesini G.
    Am J Gastroenterol; 2005 May 15; 100(5):1082-90. PubMed ID: 15842582
    [Abstract] [Full Text] [Related]

  • 9. Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study.
    Kiortsis DN, Tsouli S, Filippatos TD, Konitsiotis S, Elisaf MS.
    Nutr Metab Cardiovasc Dis; 2008 Mar 15; 18(3):207-10. PubMed ID: 17570651
    [Abstract] [Full Text] [Related]

  • 10. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome.
    Svendsen M, Helgeland M, Tonstad S.
    J Hum Nutr Diet; 2009 Feb 15; 22(1):55-63. PubMed ID: 19192027
    [Abstract] [Full Text] [Related]

  • 11. Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study.
    Nobili V, Manco M, Ciampalini P, Alisi A, Devito R, Bugianesi E, Marcellini M, Marchesini G.
    Clin Ther; 2008 Jun 15; 30(6):1168-76. PubMed ID: 18640473
    [Abstract] [Full Text] [Related]

  • 12. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
    Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G.
    Obes Res; 2000 Jan 15; 8(1):49-61. PubMed ID: 10678259
    [Abstract] [Full Text] [Related]

  • 13. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D, Ivković-Lazar T, Dragojević R, Jorga J, Stokić E, Hajduković Z.
    Med Pregl; 1999 Jan 15; 52(9-10):323-33. PubMed ID: 10624380
    [Abstract] [Full Text] [Related]

  • 14. Effect of orlistat on cardiovascular disease risk in obese adults.
    Swinburn BA, Carey D, Hills AP, Hooper M, Marks S, Proietto J, Strauss BJ, Sullivan D, Welborn TA, Caterson ID.
    Diabetes Obes Metab; 2005 May 15; 7(3):254-62. PubMed ID: 15811142
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients.
    Kaya A, Aydin N, Topsever P, Filiz M, Oztürk A, Dağar A, Kilinç E, Ekmekcioglu C.
    Biomed Pharmacother; 2004 Dec 15; 58(10):582-7. PubMed ID: 15589067
    [Abstract] [Full Text] [Related]

  • 16. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis.
    Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S.
    Am J Gastroenterol; 2003 Nov 15; 98(11):2485-90. PubMed ID: 14638353
    [Abstract] [Full Text] [Related]

  • 17. Weight loss as a treatment for nonalcoholic fatty liver disease.
    Clark JM.
    J Clin Gastroenterol; 2006 Mar 15; 40 Suppl 1():S39-43. PubMed ID: 16540766
    [Abstract] [Full Text] [Related]

  • 18. Long-term weight loss decreases the nontraditional cardiovascular risk factors interleukin-18 and matrix metalloproteinase-9 in obese subjects.
    Madsen EL, Bruun JM, Skogstrand K, Hougaard DM, Christiansen T, Richelsen B.
    Metabolism; 2009 Jul 15; 58(7):946-53. PubMed ID: 19409578
    [Abstract] [Full Text] [Related]

  • 19. Orlistat for obesity: benefits beyond weight loss.
    Hsieh CJ, Wang PW, Liu RT, Tung SC, Chien WY, Chen JF, Chen CH, Kuo MC, Hu YH.
    Diabetes Res Clin Pract; 2005 Jan 15; 67(1):78-83. PubMed ID: 15620437
    [Abstract] [Full Text] [Related]

  • 20. Impact of orlistat therapy on weight reduction in morbidly obese patients after implantation of the Swedish adjustable gastric band.
    Zoss I, Piec G, Horber FF.
    Obes Surg; 2002 Feb 15; 12(1):113-7. PubMed ID: 11868286
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.